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Photodynamic Therapy In A Cell Culture Model of Human Intimal 
Hyperplasia 
M. S. Sobeh, P. Chan, R. J. Ham, A. J. Wood and F. W. Cross 
The Royal London & St Mary's Hospitals, London, U.K. 
Objective: To investigate the effectiveness ofphotodynamic therapy (PDT) in eliminating proliferating vascular smooth 
muscle cells (VSMCs). This may have a potential role in reducing restenosis rates clinically. 
Materials and methods: Human VSMCs were successfully cultured from 15 long saphenous veins (SV) and seven 
restenotic lesions (RL) removed during revision coronary and peripheral vein2gyaft surgery. Cultured VSMCs were 
incubated with photofrin at doses of O-5 tzg/ml for 48 h, and then exposed to 4 J/cm of polychromatic light. Cell destruction 
was quantified by a colorimetric assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
Results: Results are expressed as a mean percentage survival + standard error. Cells were minimally affected by either 
photofrin alone (SV: 95.5% + 5.3; RL: 119.8 + 4.8) or light alone (SV: 75.38% + 3.99; RL: 100.1 + 11.0). The 
combination of 2 tzg/ml of photofrin and 4 J/cm 2 of polychromatic light energy, i.e. PDT, was severely toxic to cells derived 
from saphenous veins (5.52% + 0.85) as well as cells derived from restenotic lesions (9.6 + 2.3). These doses are 
comparable to doses that can be achieved in vivo. 
Conclusion: PDT in the appropriate drug and light doses can eliminate human VSMCs, including those responsible for 
vascular restenosis. 
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Introduction 
Intimal hyperplasia is one of the most critical prob- 
lems in vascular surgery. Restenosis due to intimal 
hyperplasia is demonstrated in the initial 3-24 months 
1 after revascularisation and is evident in 25% of vein 
grafts within the aortocoronary and the peripheral 
arterial circulations, ~4 in 25-50% after successful 
coronary artery balloon angioplasty s and peripheral 
endarterectomy, 6 and in up to 57% of vein graft 
78 angioplasties. • Since intimal hyperplasia lesions con- 
sist of proliferating vascular smooth muscle cells 
surrounded by their secreted extracellular matrix, 
control of their proliferation may influence intimal 
hyperplasia nd restenosis. Over 50 pharmacological 
agents have been shown to decrease the amount of 
intimal hyperplasia production in animal models, but 
none have been effective in reducing it in 
humans. 9,1° 
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Global control of vascular smooth muscle cell 
proliferation (by pharmacological methods) has so far 
proved unsuccessful. We hypothesised that local 
control i.e. a method of suppressing or eliminating 
vascular smooth muscle cells selectively at the target 
site without affecting the other elements of the vessel 
wal l  might be a viable strategy. We investigated 
photodynamic therapy (PDT) for this purpose. The 
photosensitiser is delivered intravenously and, one or 
two days later, has been shown to be selectively 
concentrated in proliferating tissue relative to healthy 
non-proliferating tissue. At this stage, the drug is 
essentially non-toxic, but when light of the correct 
wavelength is applied, cell destruction occurs rap- 
idly. 1~ The mechanism of cytotoxicity is by energy 
transfer from the light to the photosensitiser molecule 
and then to surrounding triplet oxygen molecules 
which become excited to their singlet state. Singlet 
oxygen is cytotoxic in the same way as free radicals 
are in ischaemic and other toxic states. This has 
previously been demonstrated in malignant issues, 
but rarely for benign diseases such as vascular 
stenoses. 12
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In this paper we aimed to demonstrate he effect 
of PDT on an in vitro model of human intimal 
hyperplasia utilising proliferating vascular smooth 
muscle cells derived from either undiseased long 
saphenous veins used for coronary and peripheral 
bypass grafting or restenotic lesions removed uring 
revision cardiac and peripheral vein graft surgery. 
Material and Methods 
Preparation of vascular smooth muscle cells 
Human vascular smooth muscle cells were success- 
fully cultured from 15 samples of undiseased long 
saphenous veins of patients undergoing cardiac and 
peripheral vein bypass graft surgery and seven sam- 
ples of restenotic lesions removed during revision 
coronary and peripheral vein graft surgery. Cultures 
were established in plastic flasks (Costa T75) using a 
modified explant echnique. 13Culture medium con- 
sisted of Dulbecco's Modified Eagle's Medium 
(Gibco), made up with penicillin (100 IU/ml), strepto- 
mycin (100/~g/ml), gentamicin (50/~g/ml), L-gluta- 
mine (584/~g/ml) and pyruvate (110 ~g/ml) supple- 
mented with 15% foetal calf serum (Serolab). Vascular 
smooth muscle cells displayed the characteristic 'hill 
and valley' morphology and stained positively with 
monoclonal antibody of rabbit origin raised against 
smooth muscle R actin (Dako-Patts, Sweden), a 
marker for vascular smooth muscle cells; and neg- 
atively for factor VIII-related antigen. Once vascular 
smooth muscle cells reached confluence, they were 
dislodged from their flasks by incubation with trypsin, 
split 1:2 and subcultured tothe third passage. Vascular 
smooth muscle cells were then suspended in culture 
medium, counted in a Coulter counter (Coulter 
Electronics), with the appropriate dilution correction 
being made to the count, and seeded onto 96-well 
plates (NUNC Denmark) in a volume of 100 ~zl/well. 
Plates were incubated for further 24 h to allow 
vascular smooth muscle cells to adhere before any 
further manipulation. 
Photosensitisation 
The photosensitiser photofrin (QuadraLogic Technolo- 
gies, Inc., Vancouver, Canada) was used. It was 
dissolved in phosphate buffered saline to a concentra- 
tion of 100 ~g/mL Further dilutions were made with 
culture medium. Vascular smooth muscle cells from 15 
samples of undiseased long saphenous veins and 
seven samples of restenotic lesions were removed 
from culture flasks at the third passage, washed, 
counted and seeded onto two 96-well plates at a 
confluent density in 3-12 replicate wells (average 6) 
for each photofrin concentration. Cells were allowed 
to adhere for 24 hours, the medium was exchanged 
and photofrin was added to both plates at concentra- 
tions of 0-5 ~g/ml in a volume of 100 ~1 of medium. 
All cells were kept in relative darkness by wrapping 
the plates with foil aluminium and performing all 
procedures under strict low ambient light 
conditions. 
Illumination 
Forty-eight hours after incubating both plates with 
photofrin, one plate was kept in the ambient light 
conditions as a control, while the second plate was 
illuminated with polychromatic light for 66 min. The 
light source consisted of 4 luxram 100 tungsten bulbs 
in a standard illumination box. 14 The power density 
was measured using an international light SED100 
photodiode connected to a IL700 radiometer. Since 
tungsten bulbs emit appreciable quantities of infra-red 
radiation which plays no part in photofrin activation, 
a 700 nm infra-red cut-off filter was used in conjunc- 
tion with the photodiode to perform these measure- 
ments. A power density of I + 0.1 mW/cm 2(mean + 
S.D.) was recorded for the visible radiation content 
necessary for photofrin activation giving a total 
energy density of 4 J/cm 2 over the 66 min plate 
exposure. 
Viability assay 
Cell growth and death was measured at 72 h using a 
colorimetric assay based on the uptake of 3-(4,5-dime- 
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide salt 
(MTT, Sigma) by viable cells. 10 ]zl of MTT (5 mg/ml) 
was added to each well and incubated at 37°C to allow 
cleavage of the tetrazolium ring by mitochondrial 
dehydrogenases and formation of blue formasan 
crystals. After 4 h, the residual MTT was removed and 
the crystals were dissolved by incubation with acid- 
ified (0.04 M HC1) b-isopropanol (Sigma) for 30 min. 
The full intensity of the developed colour in each well 
was read by an Elisa spectrophotometer (Anthos 
Labtec Reader 2001) and results were expressed as an 
optical density (OD) value. As uptake and cleavage of 
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MTT occurs only in living cells, the colour reaction is 
a function of the number of viable cells, 15 and can 
indicate the percentage of cells surviving after treat- 
ment. This assay was calibrated against six known cell 
densities (20, 30, 40, 50, 60, 75 × 103) determined by 
Coulter counter. Five replicates for each standard 
density value obtained from four different samples of 
normal saphenous vein were used. The percentage of 
cell survival was calculated in treatment wells com- 
pared to controls incubated without photofrin from 
plate I as follows: 
OD (test) - OD (plate) 
% Survival = x 100 
OD (control) - OD (plate) 
Statistics 
Comparisons between PDT versus photofrin and light 
alone treated cells from both saphenous veins and 
restenoses were made and statistical analysis was 
performed using the Mann-Whitney test. Statistical 
significance was defined as p < 0.05. 
Results 
The MTT assay enjoys a high degree of speed and 
precision in measuring the number and activity of 
living cells. 15'16 Validation of this assay against plating 
densities as described in the methods ection demon- 
strated a linear relationship between OD measure- 
ment and the number of VSMCs in each well (Fig. 1). 
The figure shows the best fit straight line for each of 
the cell populations derived from the four vein 
samples. The squares of the correlation coefficient 
varied between 0.939 and 0.991, showing a highly 
significant association between optical density and 
VSMC numbers (p < 0.001 in all cases). The offset on 
the points corresponding to no cells is due to the non- 
zero optical density of the 96-well plates. 
Incubating VSMCs with photofrin for 72 h in the 
dark (plate I) was non-toxic to cells derived from both 
saphenous veins and restenoses when compared with 
controls (Fig. 2). Survival rates remained unaffected 
with photofrin concentrations up to 5 ~g/ml. For 
photodynamic therapy effect (plate II), i l luminating 
these cells with 4 J / cm 2 of polychromatic light energy 
48 h after photofrin incubation caused progressive 
reduction in survival rates with increasing concentra- 
tions of photofrin. No vascular smooth muscle cells 
survival was noted at concentrations a 1.5 tzg/ml of 
photofrin. The dose response curves of cells derived 
from saphenous veins and restenoses appeared sim- 
ilar. Comparing the effect of 2 tzg/ml photofrin, 4 
J /cm 2 of polychromatic light energy and their combi- 
nation, i.e. PDT on VSMCs showed that photofrin in 
this concentration is non-toxic to cells derived from 
both saphenous veins (95.5% + 5.3 survival) and 
restenoses (119.8% _+ 4.8 survival). Treatment with 
polychromatic light alone (cells in plate II which were 
incubated without photofrin) reduced survival of 
vascular smooth muscle cells derived from saphenous 
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Fig. 1. Validation of MTT assay. Each point represents the mean of 
five replicates, the vertical bars represent _+ one standard eviation. 
The straight line is the least squares best fit calculated from these 
mean values. 
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Fig. 2. Dose response curve of vascular smooth muscle cells derived 
from saphenous veins (SV, n = 15) and restenotic lesions (RL, n = 7) 
to  photofrin alone [SV: ([3), RL (©)] and PDT [SV: (B), RL (@)]. 
Points on the curve represent mean % survival + standard error. 
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veins (75.38% + 3.9 survival) without affecting those 
derived from restenoses (100.1% + 11.0 survival). 
Photodynamic therapy, with fight and photofrin com- 
bined at the above doses was severely toxic to cells 
derived from saphenous veins (5.5% + 0.8 survival) as 
well as cells derived from restenotic lesions (9.6 + 2.3 
survival) (Fig. 3). There was clearly a highly sig- 
nificant effect of PDT compared to either photofrin- 
only or light-only controls (p < 0.0002 in all cases). 
Although vascular smooth muscle cells derived from 
restenotic lesions had significantly higher survival 
rates than those derived from saphenous veins when 
treated with photofrin and light alone (photofrin alone 
p = 0.04, light alone p = 0.02, Mann-Whitney), the dif- 
ferences between them failed to reach statistical 
significance after PDT treatment (p=0.08, Mann- 
Whitney). 
Discussion 
Since 1982, experimental therosclerotic lesions in vivo 
and human atherosclerotic plaques in vitro have been 
shown to take up preferentially haematoporphyrin 
derivatives and other photosensitising drugs when 
compared with normal arterial segmentsF -26 
Initially, the photosensitisers appear to enter 
12 27 -29 atherosclerotic lesions by diffusion, ' - whilst selec- 
tive concentration within the cellular component of 
the atheroma ppear to be delayed for a period of 
hours or days. 12A9 
Plaque photosensitisation has been found useful 
in aiding diagnosis of atheroma by detecting its 
fluorescence during endovascular procedures. 2s On 
the other hand the results of photosensitiser-aided 
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Fig. 3. Comparison between the effect of PDT versus light or 
photofrin alone on vascular smooth muscle cells derived from 
saphenous veins ([], n = 15) and restenotic lesions (m, n = 7). Values 
represent mean % survival _+ standard error. 
ablation or PDT of atherosclerotic lesions have been 
considerably less successful. ~2'17"3°-32 This failure is 
attributed to the presence of a large amount of 
acellular matrix and calcification within the atheroma 
which are unlikely to be targeted by PDT. In spite of 
the initial gloomy results, Spears has suggested that 
PDT could still be used to prevent progression of 
atherosclerosis by targeting the cellular component of 
atherosclerotic lesions in general and VSMCs in 
particular which are responsible for initiating these 
lesions. 33 This conclusion was based on the striking 
appearance of widespread necrosis of VSMCs and 
delayed fibrosis in the media of PDT-treated 
arteries. 12 
In contrast to complex atherosclerotic lesions, 
restenosis due to intimal hyperplasia is a predom- 
inantly cellular process involving proliferation and 
migration of medial vascular smooth muscle cells. The 
understanding of this process has renewed interest in 
the anti-profiferative effect of PDT for both treatment 
of established cellular lesions of intimal hyperplasia 
and prevention of proliferation after vascular 
intervention. 
Eaton et al. have shown that treating 1-week-old 
intimal hyperplasia in the rabbit carotid artery with 
PDT, using photofrin, caused significant reduction in 
the surface area of intimal hyperplasia when com- 
pared with control 5 weeks after induction of cellular 
proliferation. 34 More convincingly, Ortu et aI. have 
~" showed that using higher energy densities to activate 
a second generation photosensitiser, chloroalumin- 
ium-sulphonated phthalocyanine, can effectively 
inhibit the intimal hyperplastic response when it is 
used before or during balloon injury in the rat carotid 
arteryJ 5 
It is important o note that these and many other 
studies have been performed on experimental nimal 
models of intimal hyperplasia. Although their value in 
assessing vascular tissue responses to PDT is invalua- 
ble, it is considered that human studies are vital in this 
field. 36 Cultured human VSMCs are considered phe- 
notypically analogous to those seen in the proliferat- 
ing lesions of intimal hyperplasia, B3"37 and an increas- 
ing number of studies have recently been performed 
on this model. Gonschior et al. have found that human 
VSMCs from atherosclerotic and intimal hyperplasia 
lesions fluoresce more than cells from normal arterial 
segments after 1 hour's incubation with photofrin, by 
a factor of 3-4 times. 38 Dartsch et aI. compared the 
susceptibility of cultured human VSMCs obtained 
from normal arteries 12-14 h post mortem with those 
obtained from plaques removed surgically from 
superficial femoral arteries. They found that the 
cytotoxic effect of a combination of 1 /zg/ml of 
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dihaematoporphyrin ether and ultraviolet illumina- 
tion was four times greater in cultured VSMCs 
derived from atherosclerotic than those from non- 
atherosclerotic arteries. 39 However, in our study cells 
from normal vessels and cells from restenotic areas 
were equally susceptible to PDT at adequate concen- 
trations of photofrin and light energy. The lack of 
selectivity between VSMCs from saphenous veins and 
restenotic lesions parallels the widely reported lack of 
differential uptake and response to PDT between 
normal and neoplastic cells in culture. 4°-42 This 
finding in our opinion is of paramount importance 
since damage to normal vascular tissue could result 
during the course of PDT of vascular stenosis unless 
targeting of light illumination is implemented. We 
consider that atherosclerotic cells in the Dartsch study 
are not analogous to restenotic smooth muscle cells 
and that a component of renascence in atheroma- 
derived cells may render them more susceptible to 
inhibitory treatments. 
In spite of the convincing evidence of the in-vitro 
and in vivo studies which confirmed the ability of PDT 
to treat intimal hyperplasia, this treatment has 
remained a research tool. The failure of advancing the 
use of PDT for the treatment of restenosis is due 
principally to the absence of an adequate endo- 
vascular light system capable of delivering uniform 
and unattenuated light doses in a delineated bloodless 
field. The other main limiting factor has been the skin 
photosensitivity reaction, similar to sunburn, which 
may occur for as long as 8 weeks after photofrin 
injection following inadvertent exposure to sunlight. 43 
To overcome this undesired side effect attempts have 
been made to concentrate on the development of 
second generation photosensitisers with greatly 
reduced skin photosensitivity intervals as well as 
investigating means of delivering the photosensitisers 
by local application. 
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